These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15661405)

  • 21. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
    Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
    Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy.
    Laane E; Derolf AR; Björklund E; Mazur J; Everaus H; Söderhäll S; Björkholm M; Porwit-MacDonald A
    Haematologica; 2006 Jun; 91(6):833-6. PubMed ID: 16769587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome.
    Feller N; Schuurhuis GJ; van der Pol MA; Westra G; Weijers GW; van Stijn A; Huijgens PC; Ossenkoppele GJ
    Leukemia; 2003 Jan; 17(1):68-75. PubMed ID: 12529662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
    Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
    Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia.
    Nakasone H; Izutsu K; Wakita S; Yamaguchi H; Muramatsu-Kida M; Usuki K
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1262-9. PubMed ID: 18940681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
    Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A; Shi Y; Feng F; Lu S; He X; Han X
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma.
    Friedberg JW; Kim H; Li S; Neuberg D; Boyd K; Daley H; Fisher DC; Gribben JG; Spitzer T; Freedman AS
    Bone Marrow Transplant; 2003 Oct; 32(7):681-6. PubMed ID: 13130315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purging of peripheral blood stem cell grafts.
    Gee A
    Stem Cells; 1995 Dec; 13 Suppl 3():52-62. PubMed ID: 8747989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.
    van Stijn A; Feller N; Kok A; van der Pol MA; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Apr; 11(7):2540-6. PubMed ID: 15814631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
    Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
    Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
    Al-Mawali A; Gillis D; Hissaria P; Lewis I
    Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.